U.S. Markets open in 3 hrs 17 mins
  • Gold

    1,778.80
    +13.10 (+0.74%)
     
  • EUR/USD

    1.1669
    +0.0050 (+0.4317%)
     
  • 10-Yr Bond

    1.5840
    0.0000 (0.00%)
     
  • Vix

    16.07
    -0.23 (-1.41%)
     
  • GBP/USD

    1.3814
    +0.0087 (+0.6355%)
     
  • USD/JPY

    114.0950
    -0.2170 (-0.1898%)
     
  • BTC-USD

    62,212.39
    +1,473.03 (+2.43%)
     
  • CMC Crypto 200

    1,451.64
    +0.00 (+0.00%)
     
  • FTSE 100

    7,205.55
    +1.72 (+0.02%)
     
  • Nikkei 225

    29,215.52
    +190.06 (+0.65%)
     

Eagle Pharmaceuticals to Host Second Quarter 2021 Financial Results on August 9, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

WOODCLIFF LAKE, N.J., July 28, 2021--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (Nasdaq: EGRX) today announced that the Company will release its 2021 second quarter financial results on Monday, August 9, 2021, before the market opens.

Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows:

Date

Monday, August 9, 2021

Time

8:30 a.m. ET

Toll free (U.S.)

877-876-9173

International

785-424-1667

Webcast (live and replay)

www.eagleus.com, under the "Investor Relations" section

A replay of the conference call will be available for one week after the call's completion by dialing 888-562-2815 (US) or 402-220-7352 (International) and entering conference call ID EGRXQ221. The webcast will be archived for 30 days at the aforementioned URL.

About Eagle Pharmaceuticals, Inc.

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include RYANODEX®, BENDEKA®, BELRAPZO®, and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210728006015/en/

Contacts

Investor Relations for Eagle Pharmaceuticals, Inc:
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com